Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Crossover Study From Macitentan or Bosentan Over to Ambrisentan
The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease…
- Trial name
- Letairis (NCT02885012)
- Testing
- Ambrisentan
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Medical University of South Carolina
Pulmonary Arterial Hypertension
Remodulin® to Oral Treprostinil Transition
This multi-center, open-label study will assess the tolerability and safety of transitioning subjects with stable Pulmonary Arterial Hypertension (PAH) from continuous intravenous (IV) or subcutaneous (SC) Remodulin infusion to…
- Trial name
- NCT01588405
- Testing
- UT-15C SR
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
- Trial name
- NCT02576002
- Testing
- Assigned pulmonary hypertension medication
- Where
- United States
- Volunteers
- 2,691 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
The purpose of this multi-center, open-label, safety and tolerability study was to assess the addition of oral treprostinil (UT-15C sustained release [SR] tablets) to subjects currently receiving Tyvaso (treprostinil) inhalation…
- Trial name
- NCT01477333
- Testing
- UT-15C SR, Tyvaso Inhalation Solution
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
- Trial name
- NCT01251835
- Testing
- Sitaxsentan alone, Sitaxsentan, Rifampin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Artery Hypertension
Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH
The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the repeatability of laboratory and…
- Trial name
- REPEAT-PAH (NCT05421949)
- Testing
- Exercise group
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pulmonary Arterial Hypertension
Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography
The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT).
- Trial name
- NCT01607489
- Testing
- Dual-energy computed tomography investigation
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
- Trial name
- MAESTRO (NCT01743001)
- Testing
- Macitentan 10 mg
- Where
- 55 sites in United States, Austria and 19 more
- Volunteers
- 226 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
The purpose of this multicentre, open label, single-arm study in approximately 20 adult patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial…
- Trial name
- NCT01462565
- Testing
- current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study
Theis is a prospective, multicenter, blinded, randomized sham controlled pivotal clinical trial with a crossover at 6M, to assess the safety and effectiveness of pulmonary artery denervation with the TIVUS™ System in subjects…
- Trial name
- NCT04570228
- Testing
- Pulmonary artery denervation
- Volunteers
- 205 people
- Sponsor
- SoniVie Inc.
Pulmonary Hypertension, Pain
Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
The investigators hypothesise that pre-application of Qutenza® patches to the skin may reduce pain at the site of Remodulin® SC infusion (sited 1 to 2 weeks later at the site of Qutenza pre-application), in which case it would…
- Trial name
- NCT01393795
- Testing
- Qutenza, Tegaderm
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Effect of Food on BIA 5-1058
The aim of this study is to investigate the effect of food on the pharmacokinetic (PK) profile of BIA 5-1058 after a single dose in healthy subjects.
- Trial name
- NCT04991155
- Testing
- BIA 5-1058
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Chronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Determinants of Right Heart Remodeling in Patients With CTEPH or PAH
Right heart failure is the main cause of morbi-mortality in patients with pulmonary hypertension (PH), including patients of chronic thrombo-embolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)…
- Trial name
- PRINCEPT (NCT03205085)
- Testing
- magnetic resonance imaging, 2D and 3D trans-thoracic echocardiography, Blood samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
- Trial name
- CPETPH (NCT02061787)
- Testing
- balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
- Trial name
- NCT01112306
- Testing
- ACT-293987
- Where
- 157 sites in United States, Argentina and 36 more
- Volunteers
- 709 people
- Sponsor
- Actelion
Hypertension, Pulmonary Arterial Hypertension
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH).
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension
- Trial name
- T3PAH (NCT03528902)
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt